Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer

NCT00612586 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Enzastaurin
DRUG: Placebo
DRUG: Leucovorin (LV)
DRUG: 5-fluorouracil (5-FU)
DRUG: Bevacizumab (Bev)

Sponsor

Eli Lilly and Company

Collaborators

[object Object]